Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03710564
Brief Title: Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections (MERLIN)

First Submitted : October 16, 2018
First Submitted that Met QC Criteria : October 16, 2018
First Posted : October 18, 2018

Last Update Submitted that Met QC Criteria : July 8, 2021
Last Update Posted : July 9, 2021